Quimioterapia adjuvante para o tratamento do câncer de ovário e o cuidado farmacêutico: uma revisão integrativa

Fabiola do Socorro Barros Mendes; Maria Fâni  Dolabela

doi:10.33448/rsd-v10i16.20638

Authors

Fabiola do Socorro Barros Mendes Universidade Federal do Pará https://orcid.org/0000-0003-4289-7680
Maria Fâni Dolabela Universidade Federal do Pará https://orcid.org/0000-0003-0804-5804

DOI:

https://doi.org/10.33448/rsd-v10i16.20638

Keywords:

Ovary cancer; Adjuvant chemotherapy; Pharmaceutical care.

Abstract

Este estudo teve como objetivo analisar os tratamentos quimioterápicos adjuvantes que vêm sendo adotados para o tratamento do câncer de ovário. Bem como, propor estratégias que podem ser adotadas para o cuidado farmacêutico a este paciente. Inicialmente, foi buscado os artigos na plataforma Capes, sendo incluídos artigos revisados por pares, publicados entre 2016 a 2021 e utilizado os seguintes termos: “pharmaceutical care protocol and câncer ovary and chemotherapy adjuvante”. Foram encontrados 125 artigos e procedeu a leitura dos títulos e resumos, sendo que somente 10 artigos tiveram relação com o tema do trabalho e 7 trabalhos foram incluídos no estudo. Estes artigos, os pacientes faziam a quimioterapia convencional associado a bevacizumabe, indol-3-carbinol, epigalocatequina-3-galato, pegfilgrastin e/ou filgrastin, vígil, lisado de tumor oxidado autólogo (OC-DC) e vacina de dez peptídeos (PEP-DC), everolimo e letrozol. Os estudos demonstraram respectivamente: aumento da sobrevida livre de doença, porém é necessário mais estudos devido algumas controversas; ausência de toxicidade que exigisse alteração no regime de terapia padrão; que ao pacientes com maior pontuação de AIVD tem maior probabilidade de completar 4 ciclos de quimioterapia e menos probabilidade de apresentar toxicidade de grau 3 ou superior; melhora da resposta imune; a segurança, bem como alteração na sobrevida; uma taxa de PFS promissora, sendo que 47% teve 12 semanas e toxicidade leve. Também, o desenvolvimento de formulação Nanopartículas de Paclitaxel-LDE (lipídeos não proteicos- PTX-LDE) levou uma melhora na resposta para o câncer de ovário. O papel do farmacêutico na equipe multiprofissional é muito importante, pois envolve o acompanhamento clínico do paciente, a prevenção de agravos a saúde da equipe devido a exposição aos quimioterápicos, a manipulação dos fármacos e detecção dos problemas relacionados aos medicamentos. Em síntese, ainda são escassos os estudos que visem a busca de alternativas terapêuticas mais eficazes para o tratamento do câncer de ovário.

References

Adams G, Zekri J, Wong H, Walking J, & Green JA. (2010). Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG., 117(12), 1459-67.

Adams, G., Zekri, J., Wong, H., Walking, J. & Green, J.A. (2010). Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG., 117(12),1459-67.

Arbuck, S. G, Strauss, H., Rowinsky, E., Christian, M., Suffness, M., Adams, J., Oakes, M., McGuire, W., Reed, E., & Gibbs, H. (1993). A reassessment of cardiac toxicity associated with Taxol. J Natl CancerInst Monogr., 15:117–30.

Beaver, L. M., Yu, T. W., Sokolowski, E. I., Williams, D. E., Dashwood, R. H., & Ho, E. (2012). 3,3′- Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol., 263(3), 345–51.

Bowman, A., Gabra, H., Langdon, S. P, Lessells, A., Stewart, A., Young, A., & Smyth, J. F. (2002). CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 8, 2233–2239.

Brasil, Ministério da Saúde. (2019). Diretrizes Diagnósticas e Terapêuticas de Neoplasia maligna epitelial de ovário, 419, 109,.

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Gestão e Incorporação de Tecnologias em Saúde. (2016). Entendendo a Incorporação de Tecnologias em Saúde no SUS : como se envolver [recurso eletrônico], . 34 p.

Bristow, R. E., Baldwin, R. L., Yamada, S. D., Korc, M., & Karlan, B. Y. (1999). Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma, Cancer ,85 (3), 658–668.

Moura, A.C., de Barros Júnior, A.P., Gouveia, G.C., & de Oliveira, V.R (2018). Diretrizes Oncológicas: Câncer de Ovário. cap. 23, p.333-352.

Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W. R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P. (2015). Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specifc T cells. Science, 348(6236), 803–8.

Cesario, M. S. A., Carneiro, A. M. F.a, & Dolabela, M. F. (2020). Tratamento medicamentoso em pacientes neonatos com cardiopatia congênita: apontamentos a partir da literatura recente. Research, Society And Development, 9(11). http://dx.doi.org/10.33448/rsd-v9i11.9946

Chen, X. S., Nie, X. Q., Chen, C. M., Wu, J. Y., Wu, J., Lu, J. S., Shao, Z. M., Shen, Z. Z. & Shen, K. W. (2010). Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast câncer. Annals of Oncology, 21: 961–967. doi:10.1093/annonc/mdq041

Chen, X. S., Nie, X. Q., Chen, C. M., Wu, J. Y., Wu, J., Lu, J. S., Shao, Z. M., Shen, Z. Z., & Shen, K. W. (2010). Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast câncer. Annals of Oncology 21, 961–967. doi:10.1093/annonc/mdq041.

Colon-Otero, G., Weroha, S. J., Foster, N. R., Haluska, P., Hou, X., Wahner-Hendrickson, A. E., Jatoi, A., Block, M. S., Dinh, T. A., Robertson, M. W., & Copland, J. A. (2017). Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecologic Oncology, 146, 64–68.

Comitê de Consenso (2002). Segundo Consenso de Granada sobre problemas relacionados com medicamentos. Ars Pharm., 43(3-4), 175-184.

Cruz, L. O., Almeida, M. K. C., & Dolabela, M. F . (2020). Contributions of complementary therapies and other strategies to the treatment of schizophrenia: an integrative review. Research, Society And Development, 9(11). http://dx.doi.org/10.33448/rsd-v9i11.10376

Dale, W., Mohile, S. G., Eldadah, B. A., Trimble, E. L., Schilsky, R. L., Cohen, H. J., Muss, H. B., Schmader, K. E., Ferrell, B., Extermann, M., Nayfield, S. G., & Hurria, A. (2012). Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J. Natl. Cancer Inst. 104, 581–589.

del Carmen, M. G., Supko, J. G., Horick, N. K., Rauh-Hain, J. A., Clark, R. M., Campos, S. M., Krasner, C. N., Atkinson, T., & Birrer, M. J. (2016). Phase I/II Study of Carboplatin and Pralatrexate in Patients with Recurrent Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Cancer, 122: 3297–3306. DOI: 10.1002 / cncr.30196.

del Carmen, M. G., Fuller, A. F., Matulonis, U., Horick, N. K., Goodman, A., Duska, L. R., Penson, R., Campos, S., Roche, M., & Seiden, M. V. (2003). Phase II trial of anastrozole in women with asymptomatic mullerian câncer. Gynecol. Oncol., 91, 596–602.

Deshpande, P. R., Rajan, S., Lakshmi Sudeepthi, B., & Abdul Nazir, C. P. (2011). Patient-reported outcomes: a new era in clinical research. Perspect Clin. Res., 2 (4), 137–144.

Du Bois, A., Reuss, A., Harter, P., Pujade-Lauraine, E., Ray-Coquard, I., & Pfisterer, J. (2010). Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol., 28(10),1733-9. doi: 10.1200/JCO.2009.25.3617.

Easton, D. F., Ford, D. & Bishop, D. T. (1995). Breast and ovarian câncer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet, 56 (1), 265-71.

Fang, M. Z., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu, H., Welsh, W., & Yang, C. S. (2003). Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res., 63(22), 7563–70.

Gourley, C., Smyth, J. F., Mackean, M., Stevenson, A., Williams, A., Reed, T. R. N., Vasey, P., Gabra, H., & Langdon, S. (2006). Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC). J. Clin. Oncol., 24 (18_ suppl), 5025.

Graziani, S. R., Vital, C. G., Morikawa1, A. T., Van Eyll, B. M., Junior, H. J. F., Filho, R. K., & Maranhão, R. C. (2017). Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. Med Oncol, 34:151.

Green, M. (2001). A single, fixed-dose of Pegfilgrastin given once-per-chemotherapy cycle is as effective as daily Filgrastrim in the management of neutropenia in high-risk breast cancer. European Journal of Cancer, 37, S146–S147. doi:10.1016/s0959-8049(01)81032-7

Haefele, A., Word, B., Yongmei, X., Hammons, G. J., & Lyn-Cook, B. D. (2007). Indole-3-carbinol (I3C) modulates expression of DNA methyltransferases 1, 3a, and 3b in pancreatic cancer cells: effects of gender and a novel (C→T) polymorphism in the promoter region of DNMT 3b. Int J Cancer Prev., 2(4), 245–55.

Hurria, A., Cirrincione, C. T., Muss, H. B., Kornblith, A. B. Barry, W., Artz, A. S., Schmieder, L., Ansari, R., Tew, W. P., Weckstein, D., Kirshner, J., Togawa, K., Hansen, K., Katheria, V., Stone, R., Galinsky, I., Postiglione, J., & Cohen, H. J. (2011). Implementing a geriatris assessment in cooperative group clinical cancer trials: CALGB 360401, J. Clin. Oncol., 29, 1290–1296.

Hurria, A., Dale, W., Mooney, M., Rowland, J. H., Ballman, K. V., Cohen, H. J., Muss, H. B., Schilsky, R. L., Ferrell, B., Extermann, M., Schmader, K. E., & Mohile, S. G. (2014). Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J. Clin. Oncol., 32, 2587–2594.

Hurria, A., Levit, L. A., Dale, W, Mohile, S. G. Muss, H. B., Fehrenbacher, L., Lichtman, S. M., Bruinooge, S. S., Peres-de-Celis, E., Tew, W. P., Postow, M. A., & Cohen, H. J. (2015). Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement. J. Clin. Oncol., 33, 3826–3833.

Hurria, A., Naylor, M., & Cohen, H. J. (2013). Improving the quality of cancer care in an aging population: recommendations from an IOM report, JAMA, 310, 1795–1796.

Jiang, X-P., Rui, X-H., Guo, C-X., Huang, Y-Q., Li, Q. & Xu, Y. (2017). A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer. Oncotarget.,8 (12), 19125-36.

Kandalaft, L. E., Powell Jr., D. J., Singh, N., & Coukos, G. (2011). Immunotherapy for ovarian cancer: what's next? J. Clin. Oncol. 29 (7), 925–933.

Kavanagh, J. J., Hu, W., Fu, S., Deavers, M., Moore, C., Coleman, R. L., Levenback, C. F., Shen, D., Zheng, G., Yf, L., Mueller, P., Gershenson, D. M., Zheng, H., & Li, Y. F. (2007). Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors. J. Clin. Oncol., 25 (18_suppl), 5582.

Kiselev, V. I., Ashrafyan, L. A., Muyzhnek, E. L., Gerfanova, E. V., Antonova, I. B., Aleshikova, O. I., & Sarkar, F. H. (2018). A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study. BMC Cancer, 18:904.

Komiyama, S., Kugimiya, T., & Kubushiro, K. (2018). Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study. J. Surg. Oncol., 118, 687-693. DOI: 10.1002/jso.25187.

Krasner, C. N., Debernardo, R. L., Findley, M., Penson, R., Matulonis, U., Atkinson, T., Roche, M., & Seiden, M. V. (2005). Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian câncer. J. Clin. Oncol., 23 (16_suppl), 5063.

Lawrie, T. A., Winter-Roach, B. A., Heus. P. & Kitchener, H. C. (2015). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev., 17 (12). https://doi.org/10.1002/14651858.CD004706.pub5.

Li, Y., Kong, D., Wang, Z., & Sarkar, F. H. (2010) Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res., 27(6), 1027–41.

Li, Y., Li, X., & Guo, B. (2010). Chemopreventive agent 3,3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res., 70(2), 646–54.

Li, Y., & Tollefsbol, T. O. (2010). Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem., 17(20), 2141–51.

Li, Y. F., Hu, W., Fu, S. Q., Li, J. D., Liu, J. H., & Kavanagh, J. J. (2008). Aromatase inhibitors in ovarian cancer: is there a role? Int. J. Gynecol. Cancer ,18, 600–614.

Li, F. , Deng, L., Jackson, K. R., Talukder, A. H., Katailiha, A. S., Bradley, S. D., Zou, Q., Chen, C., Huo, C., Chiu, Y., Stair, M., Feng, W., Bagaev, A., Kotlov, N., Svekolkin, V., Ataullakhanov, R., Miheecheva, N., Frenkel, F., Wang, Y., Zhang, M., Decker, W. K., Sonnemann, H. M., Roski, J., Forget, M. E., Davies, M. A., Bernatchez, C., Yee, C., Basset, R., Hwu, P., Du, X., & Lizee, G. (2021) Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer, 9(7), e002531. doi: 10.1136/jitc-2021-002531.

Luiz, B. M., Miranda, P. F., Maia, E. M. C., Machado, R. B., Giatti, M. J. L., Antico Filho, A., & Borges, J. B. R. (2009) Estudo Epidemiológico de Pacientes com Tumor de Ovário no Município de Jundiaí no Período de Junho de 2001 a Junho de 2006. Revista Brasileira de Cancerologia, 55(3), 247-253.

Lyn-Cook, B. D., Mohammed, S. I., Davis, C., Word, B., Haefele, A., Wang, H., & Hammons, G. (2010). Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3-carbinol. Anticancer Res., 30(12), 4907–13.

Maier-Lenz, H., Hauns, B., Haering, B., Koetting, J., Mross, K., Unger, C., Bauknecht, T., du Bois, A., Meerpohl, H. G., Hollaender, N., & Diergarten, K. (1997). Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics. Semin Oncol., 24(6 Suppl 19),S19-16–S19-1.

Moura, A. C. C. de, Barros Júnior, A. P. de, Gouveia, G. de C & Oliveira, V. R. (2018). Câncer De Ovário. Diretrizes Oncológicas, 23, 333-352.

Oh, J., Barve, M., Matthews, C. M., Koon, E. C., Heffernan, T. P., Fine, B., Grosen, A., Bergman, M. K., Fleming, E. L., DeMars, L. R., West, L., Spitz, D. L., Goodman, H., Hancock, K. C., Wallraven, G., Kumar, P., Bognar, E., Manning, L., Pappen, B. O., Adams, N., Senzer, N., & Nemunaitis, J. (2016). Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian câncer. Gynecologic Oncology, 143, 504–510

.

Osborne, C. K., Shou, J., Massarweh, S. & Schiff, R. (2005). Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast câncer. Clin. Cancer Res., 11, 865s–870s.

Ott, P. A., Govindan, R., Naing, A., Friedlander, T. W., Margolin, K., Lin, J. J., Bhardawaj, N., Hellman, M. D., Srinivasan, L., Greshock, J., Moles, M., Gaynor, R. B., Goldstein, M. J., & Hu-Lieskovan, S. (2018). A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC and bladder cancer. Ann Oncol., 29(suppl_8), viii400–41. https ://doi.org/10.1093/annonc/mdy288.

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., Chen, C., Olive1, O., Carter, T. A., Li, S., Lieb, D. J., Eisenhaure, T., Gjini, E., Stevens, J., Lane, W. J., Javeri, I., Nellaiappan, K., Salazar, A. M., Daley, H., Seaman, M., Buchbinder, E. I., Yoon, C. H., Harden, M., Lennon, N., Gabriel, S., Rodigo, S. J., Barouch, D. H., Aster, C. J., Getz, G., Wucherpfennig, K., Neuberg, D., Ritz, J., Lander, E. S., Fritsch, E. F., Hacohen, N., & Wu1, C. J. (2017). An immuno genic personal neoantigen vaccine for patients with melanoma. Nature, 547, 217–21.

Pandey, M., Shukla, S., & Gupta, S. (2010). Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer, 126(11), 2520–33.

Papadimitriou, C. A., Markaki, S., Siapkaras, J., Vlachos, G., Efstathiou, E., Grimani, I., Hamilos, G., Zorzou, M., & Dimopoulos, M., (2004). Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology, 66, 112–117.

Raber-Durlacher, J. E., Weijl, N. I., Abu Saris, M., de Koning, B., Zwinderman, A. H & Osanto, S.(2000). Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer, 8:366–71.

Rauh-Hain, J. A., Melamed, A., Wright, A., Gockley, A., Clemmer, J. T., Schorge, J. O., Del Carmen, M. G., & Keating, N. L. (2017). Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol., 3 (1),76-82.

.

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B. P., Simon, P., Lower, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., Omokoko, T., Vormehr, M., Albrecht, C., Paruzynski, A., Kuhn, A.N., Buck, J., Heesch, S., Schreeb, K.H., Müller, F., ..., Türeci, O. (2017). Personalized RNA mutanome vaccines mobilize poly-specifc therapeutic immunity against cancer. Nature, 547(7662), 222–6.

Sarivalasis, A., Boudousquié. C., Balint, K., Stevenson, B. J., Gannon, P. O., Iancu, E. M., Rossier, L., Lluesma, S. M., Mathevet, P., Sempoux, C., Coukos, G., Dafni, U., Harari, A., Bassani-Sternberg, M., & Kandalaft, L. E. (2019). A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP‑DC) or with tumor lysate (OC‑DC) in patients with advanced high‑grade ovarian serous carcinoma. Transl Med, 17:391.

Schietinger, A., Philip, M., & Schreiber, H. (2008). Specifcity in cancer immunotherapy. Semin Immunol., 20(5), 276–85.

Senzer, N., Barve, M., Kuhn, J., Melnyk, A., Beitsch, P., Lazar, M., Lifshitz, S., Magee, M., Oh, J., Mill, S.W., Bedell, C., Higgs, C., Kumar, P., Yu, Y., Norvell, F., Phalon, C., Taquet, N., Rao, D.D., Wang, Z., ... Nemunaitis, J. (2012). Phase I trial of “bishRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced câncer. Mol. Ther. 20 (3), 679–686.

Senzer, N., Barve, M., Nemunaitis, J., Kuhn, J., Melnyk, A., Beitsch, P., Magee, M., Oh, J., Bedell, C., Kumar, P., Rao, D.D., Pappen, B.O., Wallraven, G., Brunicardi, F.C., & Maples, P.B. (2013). Long term follow up: phase I trial of “bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell” immunotherapy (FANG™) in advanced câncer. Journal of Vaccines and Vaccination, 4 (8), 209.

Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000). Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3- OH kinase. Nature, 407, 538–541

Sopik, V., Rosen, B., Giannakeas, V., & Narod, S. A. (2015). Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecol Oncol., 138, 757-61.

Strickland, D. K., Kounnas, M. Z., & Argraves, W. S. (1995). LDL receptor related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J., 9:890–8

Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin,M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med, 336 (20), 1401-8. 10.1056/NEJM199705153362001

Tchekmedyian, N. S., Liem, A. K., Quan, E. T., Burtzo, D. M. & Ucar, K. (2006). Aromatase inhibitor therapy for estrogen receptor positive ovarian câncer. J. Clin. Oncol., 24 (18_suppl), 15038.

Verma, S., Alhayki, M., Le, T., Baines, K., Rambout, L., Hopkins, L. & Fung Kee Fung, M. (2006). Phase II study of exemestane (E) in refractory ovarian cancer (ROC). J. Clin. Oncol., 24 (18_suppl), 5026.

Von Gruenigen, V. E., Huang, H. Q., Beumer, J. H., Lankes, H. A., Tew, W., Herzog, T., Hurria, A., Mannel, R. S., Rizack, T., Landrum, L. M., Rose, P. G., Salani, R., Bradley, W. H., Rutherford, T. J., Higgins, R. V., Secord, A. A., & Fleming, G. (2017). Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 144, 459–467.

Weiss, R.B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker Jr, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) Hypersensitivity reactions from Taxol. J Clin Oncol., 8, 1263–8.

Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Exterman, M., Falandry, C., Artz, A., Brain, E., Colloca, G., Flamaing, J., Karnakis, D., Kenis, C., Audidio, R. A., Mohile, S., Repetto, L., Leeuwen, B. V., Milisen, K., & Hurria, A. (2014). International Society of Geriatric Oncology consensus on geriatric assessment in older patients with câncer. J. Clin. Oncol., 32 (24), 2595–2603.

World Ovarian Cancer Coalition. About ovarian câncer. (2021). https://worldovariancancercoalition.org/about-ovarian-cancer/what-is-ovarian-cancer/.

Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., Olawaiye, A. B., Oldham, J., Salani, R., Sparaccio, D., Tew, W. P., Vergote, I., & Edelson, M. I. (2016). Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol., 34(28), 3460-73.

Wu, T. Y., Khor, T. O., Su, Z. Y., Saw, C. L., Shu, L., Cheung, K. L., Huang, Y., Yu, S., & Kong, A. T. (2013). Epigenetic modifications of Nrf2 by 3,3′-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. The AAPS J., 15(3):864–74.

Adjuvant chemotherapy for the treatment of ovarian cancer and pharmaceutical care: an integrative review

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

JOURNAL METRICS

Language

Make a Submission